Assessment of alpha-galactosylceramide as a novel adjuvant for pandemic influenza: A virua vaccine

α-半乳糖神经酰胺作为大流行性流感新型佐剂的评估：病毒疫苗

• 批准号: nhmrc : 400584
• 负责人: Dr Ian Barr
• 金额: $ 14.67万
• 依托单位: The University of Melbourne
• 依托单位国家: 澳大利亚
• 项目类别: NHMRC Strategic Awards
• 财政年份: 2006
• 资助国家: 澳大利亚
• 起止时间: 2006-01-01 至 2007-12-31
• 项目状态: 已结题
• 来源: https://researchdata.edu.au/assessment-alpha-galactosylceramide-virua-vaccine/99218
• 关键词: Assessment; alpha; galactosylceramide; novel; adjuvant

The occurrence of human infections with pathogenic avian H5N1 Influenza A viruses was the first documentation of these viruses demonstrating an ability to directly transmit from birds to humans. The virulent nature of these infections, and the fact that there is no pre-existing immunity to these viruses in the human population has raised the concern that these viruses may emerge to cause the next influenza pandemic. Vaccination is our most effective way of protecting against influenza infection, however there are no commercially available avian influenza vaccines available. Moreover, recent evidence suggests current vaccines strategies may be less than effective. This proposal aims to evaluate the efficacy of a novel vaccine strategy that promotes immune protection against a potential pandemic influenza strain.

人类感染致病性H5N1甲型禽流感病毒的发生是这些病毒首次证明能够从禽类直接传播给人类。这些感染的毒性，以及人类对这些病毒没有预先免疫的事实，引起了人们对这些病毒可能出现导致下一次流感大流行的担忧。疫苗接种是预防流感感染最有效的方法，但市面上并没有禽流感疫苗。此外，最近的证据表明，目前的疫苗策略可能不够有效。本建议旨在评估一种促进对潜在大流行性流感毒株的免疫保护的新型疫苗策略的功效。